Nebenwirkungen · Hulio
Hulio 20 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 16
HOS-138785 · Präparat HOS-098248
In controlled and open label adult and paediatric studies with adalimumab, serious infections (including fatal infections, which occurred rarely) have been reported, which include reports of tuberculosis (including miliary and extra-pulmonary locations) and invasive opportunistic infections (e.g. disseminated or extrapulmonary histoplasmosis, blastomycosis, coccidioidomycosis, pneumocystis, candidiasis, aspergillosis and listeriosis). Most of the cases of tuberculosis occurred within the first eight months after initiation of therapy and may reflect recrudescence of latent disease.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-30T10:07:00Z · SHA-256 52f13e987d7f56f9469be0c97cb08298d55918c256d40a958b2e53f25def7ca4 · Passage ae983eb38c96106bd7ec15f87934324f78a208b45a03dff8a4e8344c96822496 · Zeichen 15713–16301 im Abschnitt